Skip to main content
US EQUITIES AFTER-HOURS CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
ON

ONCStock

Nasdaq Global Select Market · Healthcare · CH

$403.60 last close 2026-11-18
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment ONC's does — no target price to set, unlike a price alert.

Stable Ratio screen, 4 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
COMPLIANT
Per our in-house ratio engine
4 of 7 pass our own screen — the standards disagree
Purification 1.30% *HTR non-permissible income 1.32%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
🟢 STRONG BUY SETUP
Strong confluence across multiple layers — outperforming the market by 10.1%, RSI in healthy zone. High conviction...
Scores: 4 bullish / 0 bearish
41
of 100
Setup confidence — system conviction, not win probabilityD

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

ORB · SCALP
Entry
$406.77
Stop
$402.70
Target
$414.91
Risk : Reward 2.0R

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure2 of 5 timeframes bullish · 43.5% aligned
VWAPPrice below VWAP ($413.55)
VolumeRelative volume 2.3× the 20-day average
Momentum10-day rate of change +7.2%
Overall readSTRONG BUY SETUP

ONC is currently considered halal (Sharia-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Price target
$469.23
+16.3% · 27 analysts
Institutional own.
34.5%
of shares
Momentum (10d)
+7.2%
rate of change
SMC grade
D · 41
43.5% aligned
1.30% *
Purification ratio (secondary provider, uncertain)
1.32%
Non-permissible income — HTR, from filings (2025-12-31)
D · 41
SMC grade — 43.5% timeframe alignment
+7.2%
Rate of change (10d)
$469.23
Price target (+16.3%) · 27 analysts
34.5%
Institutional ownership

How the status reached this point

Compliant · status tracked since Nov 17, 2026

No change to ONC’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 17, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-06-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $40.6B as of 2026-09-09. At the 2026-11-18 close it is about $46.8B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 2.4% (2.8% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 11.3% (13.0% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 2.81% 30.00% Pass(27.2pp buffer)
Interest-bearing investments 12.99% 30.00% Pass(17.0pp buffer)
Non-permissible income 1.32% 5.00% Pass(3.7pp buffer)
Usmani Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 12.46% 33.00% Pass(20.5pp buffer)
Interest-bearing investments 57.55% 33.00% Fail(24.6pp over)
Non-liquid assets 30.94% at least 20.00% Pass(10.9pp above the floor)
Non-permissible income 1.32% 5.00% Pass(3.7pp buffer)
MSCI Fail 2 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 12.46% 33.33% Pass(20.9pp buffer)
Cash + interest-bearing securities 57.55% 33.33% Fail(24.2pp over)
Accounts receivable 69.06% 33.33% Fail(35.7pp over)
Non-permissible income 1.32% 5.00% Pass(3.7pp buffer)
FTSE Fail 2 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 11.69% 33.33% Pass(21.6pp buffer)
Cash + interest-bearing securities 57.55% 33.33% Fail(24.2pp over)
Accounts receivable 69.06% 50.00% Fail(19.1pp over)
Non-permissible income 1.32% 5.00% Pass(3.7pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 4.05% 33.00% Pass(28.9pp buffer)
Cash + interest-bearing securities 18.73% 33.00% Pass(14.3pp buffer)
Accounts receivable 3.75% 33.00% Pass(29.3pp buffer)
Non-permissible income 1.32% 5.00% Pass(3.7pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 4.78% 33.00% Pass(28.2pp buffer)
Cash + interest-bearing securities 22.06% 49.00% Pass(26.9pp buffer)
Accounts receivable 4.41% 49.00% Pass(44.6pp buffer)
Non-permissible income 1.32% 5.00% Pass(3.7pp buffer)
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 4.78% 33.33% Pass(28.6pp buffer)
Cash + interest-bearing securities 22.06% 33.33% Pass(11.3pp buffer)
Accounts receivable 26.47% 49.00% Pass(22.5pp buffer)
Non-permissible income 1.32% 5.00% Pass(3.7pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)non permissible income ratio 3.7pts
Usmani (% of total assets)non permissible income ratio 3.7pts
Dow Jones Islamic Market (% of 24-mo avg market cap)non permissible income ratio 3.7pts
MSCI Islamic Index (% of total assets)receivables ratio 35.7pts
Usmani (% of total assets)investments ratio 24.6pts
MSCI Islamic Index (% of total assets)cash and interest ratio 24.2pts

The numbers the ratios are built from

Read from ONC's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $5.3B 2025-12-31 RevenueFromContractWithCustomerExcludingAssessedTax
Interest-bearing debtShort and long-term borrowings $1.1B 2026-06-30 LongTermDebtNoncurrent, LongTermDebtCurrent
Cash and interest-bearing securitiesCash, equivalents and marketable securities $5.3B 2026-06-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $9.2B 2026-06-30 Assets
Market capDenominator for AAOIFI $40.6B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $341.5B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $396.9B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $70.5M 2025-12-31 InvestmentIncomeInterest

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2026-06-30. Income statement as of 2025-12-31. Screened 2026-09-09.

A newer filing exists: our EDGAR watch has seen one since this screen and it is queued for re-screening. The figures below are from the filings named, not the newer one.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$9.2B
    Assets · balance sheet as of 2026-06-30
  • Interest-bearing debt$1.1B
    LongTermDebtNoncurrent, LongTermDebtCurrent · balance sheet as of 2026-06-30
  • Cash and interest-bearing securities$5.3B
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · balance sheet as of 2026-06-30
  • Receivables$1.1B
    AccountsReceivableNetCurrent · balance sheet as of 2026-06-30
  • Revenue$5.3B
    RevenueFromContractWithCustomerExcludingAssessedTax · income statement as of 2025-12-31
  • Interest income (non-permissible)$70.5M
    InvestmentIncomeInterest · income statement as of 2025-12-31
  • Market cap$40.6B
    Market-data quote at screen time, 2026-09-09 · not a filing figure, so no link

What changed, and when

Verdict history for ONC. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for ONC has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 4 pass and 3 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-06-30; market cap as stored on 2026-09-09.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's debt ratio (2.8% against a 30% line) would only fail if the market cap fell by 91%, to $3.8B. At the 2026-11-18 close it would read 2.4%.

AAOIFI's investments ratio (13.0% against a 30% line) would only fail if the market cap fell by 57%, to $17.6B. At the 2026-11-18 close it would read 11.3%.

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —
INCYIncyte Corp. $25.9B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold ONC

10 of the 213 funds whose filed holdings we currently hold own ONC shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns ONC.

Shariah funds
FundONC in fundFund compliant by weight
SPWO SP Funds S&P World (ex-US) ETF 0.26% 87%
Other funds
FundONC in fundFund compliant by weight
BGLFX Baillie Gifford Long Term Global Growth Fund Also BGLOX, BGLTX 2.13% 58%
PRIAX Global Emerging Markets Fund 0.63% 60%
RGLAX American Funds Global Insight Fund Also RGLBX, RGLEX, RGLFX, RGLGX, RGLHX, RGLJX 0.55% 52%
RIVAX American Funds International Vantage Fund Also RIVIX, RIVKX 0.33% 46%
CEUAX EUPAC Fund 0.14% 53%
PRDMX T. Rowe Price Diversified Mid-Cap Growth Fund, Inc. 0.12% 58%
RGGIX T. Rowe Price Global Growth Stock Fund 0.11% 47%
ACWX iShares MSCI ACWI ex U.S. ETF 0.05% 46%
IXUS iShares Core MSCI Total International Stock ETF 0.05% 45%

Sorted by ONC’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names ONC once, so a bond is not counted as the shares; 2 more funds name ONC in a way we cannot separate from its bonds, and are not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding ONC
InvestorFirmPositionWeightAs of
Ken Griffin Citadel Advisors $197M 0.0% 2026-09-30
Israel Englander Millennium Management $102M 0.0% 2026-09-30
Peter Brown Renaissance Technologies $51M 0.1% 2026-09-30
Sarah Ketterer Causeway Capital Management $20M 0.2% 2026-09-30
Baillie Gifford Baillie Gifford & Co $5M 0.0% 2026-09-30
Jefferies Jefferies Financial Group $1M 0.0% 2026-09-30
Ken Fisher Fisher Asset Management $0M 0.0% 2026-09-30
David Shaw D. E. Shaw & Co. $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

424.00383.07342.13301.20260.272025-11-192026-05-212026-11-18

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
402.12
S2
404.61
S1
408.94
PIVOT
411.43
R1
415.76
R2
418.25
R3
422.58

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
336.93 – 384.77
±6.63% from 360.85, made 2026-09-26 · resolves 2026-10-03
STRONG BUY
from 19 indicators
77.1% of our last 20463 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.1% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG BUY
19 indicators
OscillatorsSTRONG BUY
3 buy · 4 neutral · 0 sell
Moving averagesSTRONG BUY
10 buy · 0 neutral · 2 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)57.80NEUTRAL
Stochastic %K (14)72.60NEUTRAL
CCI (20)45.35NEUTRAL
Williams %R (14)-27.40NEUTRAL
MACD (12,26,9)1.21BUY
ROC (10)6.83BUY
Momentum (10)25.82BUY
EMA (10)406.06SELL
SMA (10)411.62SELL
EMA (20)395.77BUY
SMA (20)391.11BUY
EMA (30)388.27BUY
SMA (30)382.07BUY
EMA (50)377.39BUY
SMA (50)372.52BUY
EMA (100)359.23BUY
SMA (100)354.38BUY
EMA (200)340.59BUY
SMA (200)328.78BUY

About ONC

Healthcare · Biotechnology

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

beonemedicines.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-11-06

ORB
Type · SCALP
406.77
Entry
402.70
Stop
414.91
Target
LOSS
Outcome · exit 402.70 (-1.00%)

Stop 402.70 Now 403.60 Target 414.91

Verdict

🟢 STRONG BUY SETUP

Strong confluence across multiple layers — outperforming the market by 10.1%, RSI in healthy zone. High conviction entry. Use `!plan ONC [entry] [stop] [target]` to size the position properly.

Scores: 4 bullish / 0 bearish

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 64
⏰ 4H BEARISH 38
🕐 1H BEARISH 98
⏱ 15-Min BULLISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

+7.2%
Rate of change (10d)
2.3×
Volume vs its 20-day average
12.70
MACD (no fresh cross)
$403.83
Volume POC (today)
$403.19 – $406.29
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.